5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine
- 1 April 1989
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 34 (4) , 573-578
- https://doi.org/10.1007/bf01536335
Abstract
Uncertainty regarding the concentration of 5-ASA within the mucosal interstitium has been a major limitation of defining the protective mechanisms of 5-ASA in intestinal inflammation. Therefore, we measured the concentration of 5-ASA in intestinal lymph and venous plasma during luminal perfusion of the cat small and large intestine with 10 mM 5-ASA. Blood and lymph flows were measured in each segment. 5-ASA and N-acetyl-5-ASA were extracted from plasma and lymph and quantified using fluorescence spectroscopy. Luminal perfusion of the terminal ileum with 5-ASA resulted in the following concentration profile: intestinal venous plasma (143±30 μg/ml) ≫ lymph (43 ±17 μg/ml)=systemic arterial plasma (40±11 μg/ml). In the colon the local venous plasma concentration of 5-ASA was 20±6 μg/ml compared to 2.0±1.0 μg/ml in systemic arterial plasma. N-Acetyl-5-ASA was found to comprise less than 5% of the total metabolite concentration in both ileum and colon. We also found that 58% of luminal 5-ASA was absorbed per minute in the terminal ileum, whereas only 3%/min was absorbed from the colon. The results of this study suggest that: (1) the mucosal interstitial concentration of 5-ASA in the terminal ileum and colon are approximately 100 μg/ml (654 μM) and 20 μg/ml (164 μM), respectively; and (2) the rate of 5-ASA absorption in the terminal ileum is approximately seven times greater than that in the colon.Keywords
This publication has 22 references indexed in Scilit:
- The scavenging of oxidants by sulphasalazine and its metabolitesBiochemical Pharmacology, 1987
- Effect of anti-inflammatory drugs on xanthine oxidase and xanthine oxidase induced depolymerization of hyaluronic acidInflammation Research, 1985
- Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.Gut, 1985
- Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitisBiochemical Pharmacology, 1983
- Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.Gut, 1982
- Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.Journal of Clinical Investigation, 1982
- Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's DiseaseNew England Journal of Medicine, 1980
- Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.Gut, 1980
- The Effect of Sulfasalazine and Its Active Components on Human Polymorphonuclear Leukocyte Function in Relation to Ulcerative ColitisActa Medica Scandinavica, 1979
- AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINEThe Lancet, 1977